Department of Medicine, New York City Health and Hospitals/ Lincoln, New York City, New York, USA
Department of Medicine, New York City Health and Hospitals/ Lincoln, New York City, New York, USA.
BMJ Open. 2021 Oct 26;11(10):e051045. doi: 10.1136/bmjopen-2021-051045.
Dynamics of humoral immune responses to SARS-CoV-2 antigens following infection suggest an initial decay of antibody followed by subsequent stabilisation. We aim to understand the longitudinal humoral responses to SARS-CoV-2 nucleocapsid (N) protein and spike (S) protein and to evaluate their correlation to clinical symptoms among healthcare workers (HCWs).
A prospective longitudinal study.
This study was conducted in a New York City public hospital in the South Bronx, New York.
HCWs participated in phase 1 (N=500) and were followed up 4 months later in phase 2 (N=178) of the study. They underwent SARS-CoV-2 PCR and serology testing for N and S protein antibodies, in addition to completion of an online survey in both phases. Analysis was performed on the 178 participants who participated in both phases of the study.
Evaluate longitudinal humoral responses to viral N (qualitative serology testing) and S protein (quantitative Mount Sinai Health System ELISA to detect receptor-binding domain and full-length S reactive antibodies) by measuring rate of decay.
Anti-N antibody positivity was 27% and anti-S positivity was 28% in phase 1. In phase 1, anti-S titres were higher in symptomatic (6754 (5177-8812)) than in asymptomatic positive subjects (5803 (2825-11 920)). Marginally higher titres (2382 (1494-3797)) were seen in asymptomatic compared with the symptomatic positive subgroup (2198 (1753-2755)) in phase 2. A positive correlation was noted between age (R=0.269, p<0.01), number (R=0.310, p<0.01) and duration of symptoms (R=0.434, p<0.01), and phase 1 anti-S antibody titre. A strong correlation (R=0.898, p<0.001) was observed between phase 1 titres and decay of anti-S antibody titres between the two phases. Significant correlation with rate of decay was also noted with fever (R=0.428, p<0.001), gastrointestinal symptoms (R=0.340, p<0.05), and total number (R=0.357, p<0.01) and duration of COVID-19 symptoms (R=0.469, p<0.001).
Higher initial anti-S antibody titres were associated with larger number and longer duration of symptoms as well as a faster decay between the two time points.
感染后针对 SARS-CoV-2 抗原的体液免疫反应的动力学表明抗体首先衰减,随后稳定。我们旨在了解针对 SARS-CoV-2 核衣壳(N)蛋白和刺突(S)蛋白的纵向体液反应,并评估其与医护人员(HCWs)临床症状的相关性。
前瞻性纵向研究。
这项研究在纽约市布朗克斯区的一家纽约市公立医院进行。
HCWs 参加了第 1 阶段(N=500),并在研究的第 2 阶段(N=178)后 4 个月进行了随访。他们接受了 SARS-CoV-2 PCR 和针对 N 和 S 蛋白抗体的血清学检测,并在两个阶段都完成了在线调查。对参加了研究的两个阶段的 178 名参与者进行了分析。
通过测量衰减率,评估针对病毒 N(定性血清学检测)和 S 蛋白(定量西奈山卫生系统 ELISA 检测受体结合域和全长 S 反应性抗体)的纵向体液反应。
第 1 阶段抗-N 抗体阳性率为 27%,抗-S 抗体阳性率为 28%。第 1 阶段,症状性阳性(6754(5177-8812))比无症状性阳性者(5803(2825-11920))的抗-S 滴度更高。第 2 阶段,无症状性阳性者的抗-S 滴度略高(2382(1494-3797))与无症状性阳性亚组(2198(1753-2755))。年龄(R=0.269,p<0.01)、数量(R=0.310,p<0.01)和症状持续时间(R=0.434,p<0.01)与第 1 阶段抗-S 抗体滴度呈正相关。第 1 阶段滴度与两阶段之间抗-S 抗体滴度衰减之间存在很强的相关性(R=0.898,p<0.001)。与衰减率有显著相关性的还有发热(R=0.428,p<0.001)、胃肠道症状(R=0.340,p<0.05)、COVID-19 症状的总数量(R=0.357,p<0.01)和持续时间(R=0.469,p<0.001)。
较高的初始抗-S 抗体滴度与更多的症状数量和更长的症状持续时间以及两次时间点之间更快的衰减有关。